Biosimilars could impact US Remicade sales by 15% in 2017, says J&J
Johnson & Johnson has predicted a 10-15% erosion in sales of Remicade (infliximab) in 2017 following Pfizer’s “at-risk biosimilar launch of Inflectra.”
Archives for January 25, 2017
Wuxi Biologics files IPO prospectus aiming to be gateway to China
Wuxi Biologics has confirmed its intention to go public in an IPO application that reveals the contracter has seen revenue double and profits increase three-fold since 2014.
FDA hits UK state-owned CDMO with warning over leukemia drug production
Porton Biopharma says it is undergoing a manufacturing review to address US FDA concerns about the production of Jazz Pharmaceuticals’s orphan drug Erwinaze.